Ask Simulink Copilot how to make a design change in your model and get actionable, step-by-step guidance. Image courtesy of MathWorks. In this Special Focus Issue, learn about the latest developments ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Pills, tablets and capsules on world map with charts blue background. International ...

Generate:Biomedicines has earmarked $300 million of its IPO funds to complete a pair of phase 3 asthma trials for its anti-TSLP antibody GB-0895. (Fabrice Cabaud/Stock/Getty Images Plus) ...

Generate Biomedicines Inc. raised $400 million in an initial public offering, pricing its shares at the midpoint of the marketed range. The Somerville, Massachusetts-based drug developer sold 25 ...

Generate Biomedicines Inc., a biotechnology firm using artificial intelligence in drug development, is seeking to raise as much as $425 millon in an initial public offering, as listing activity in the ...

Systems like OpenAI’s GPT-5 are accelerating research in math, biology and chemistry. But there is a debate over whether it can do that work on its own. Credit...Agnes Jonas Supported by By Cade Metz ...

This research is dedicated to improving the control system of wind turbines (WT) to ensure optimal efficiency and rapid responsiveness. To achieve this, the fuzzy logic control (FLC) method is ...

Flagship Pioneering-backed artificial intelligence start-up Generate:Biomedicines has attracted another big pharma partnership, this time with Novartis. The wide-ranging deal, worth up to $1 billion, ...

SOMERVILLE, Mass.--(BUSINESS WIRE)--Generate:Biomedicines (“Generate”) today announced a multi-target collaboration with Novartis (NYSE: NVS) to discover and develop protein therapeutics across ...

Novartis will apply Generate:Biomedicines’ generative artificial intelligence (AI) platform to discover and develop protein therapeutics for multiple unspecified disease areas, through a collaboration ...